Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26988ArticlesСтатьиResearch ArticleClinical experience with abiraterone acetate application in patients with castration-resistant prostate cancerОпыт клинического применения абиратерона ацетата в лечении больных кастрационно-резистентным раком предстательной железыGridnevaYa VГридневаЯна Владимировна

канд. мед. наук, врач отд-ния урологии

MatveevV BМатвеевВсеволод Борисович

д-р мед. наук, проф., зав. отд-нием урологии

KupchanD ZКупчанДина Зурабовна

рук. отд-ния организации и проведения клинических исследований

KalininS AКалининСергей Анатольевич

ассистент каф. онкологии и лучевой терапии

PetersM VПетерсМария Витальевна

ассистент каф. онкологии

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, МоскваГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, МоскваГБОУ ДПО РМАПО Минздрава России, Москва15092014163VOL 16, NO3 (2014)ТОМ 16, №3 (2014)949609042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26988

In a recent randomized, double-blind, phase III clinical trials among patients with metastatic castration-resistant prostate cancer (CRPC) progressing on androgen-deprivation therapy or after docetaxel chemotherapy, abiraterone acetate was shown to significantly prolong radiographic progression free survival and overall survival compared with prednisone alone, even in symptomatic patients and patients having visceral metastases and high level of prostate specific antigen at baseline. Here we present our own experience with abiraterone acetate in patients who represent negative prognostic factors of castration-resistant prostate cancer outside of clinical trials. 25 metastatic CRPC patients were treated with abiraterone acetate from 2012 to 2014.

Недавние рандомизированные исследования III фазы по оценке эффективности абиратерона ацетата у больных метастатическим кастрационно-резистентным раком предстательной железы (КРРПЖ), как сразу после регистрации кастрационной резистентности, так и после прогрессии на доцетакселе, показали значительное увеличение времени до радиографической прогрессии и общей выживаемости, в том числе у пациентов с наличием выраженного болевого синдрома, высоким уровнем простатоспецифического антигена и висцеральными метастазами. В данной статье мы представляем собственный опыт применения абиратерона ацетата у больных метастатическим КРРПЖ c наличием неблагоприятных факторов прогноза выживаемости. в исследование вошли 25 пациентов с метастатическим КРРПЖ, получавших терапию абиратероном.

abiraterone acetatecastration-resistant prostate cancerабиратерона ацетаткастрационно-резистентный рак предстательной железыHellerstedt B.A, Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-79.Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15: 39-47.Scher H.I, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59.Tannock I.F, De Wit R, Berry W.R et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.Petrylak D.P, Tangen C.M, Hussain M.H et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.Saad F, Gleason D.M, Murray R et al. A randomized, placebo - controlled trial of zoledronic acid in patients with hormone - refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.Sternberg C.N, Petrylak D.P, Sartor O et al. Multinational, double - blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate - refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8.Engel-Nitz N.M, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration - resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011; 3: 233-45.Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population - based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706-8.Kantoff P.W, Higano C.S, Shore N.D et al. Sipuleucel-T immunotherapy for castration - resistant prostate cancer. N Engl J Med 2010; 363: 411-22.Mottet N et al. Guidelines on prostate cancer. Eur Urol 2014; 65 (1): 124-37; Eur Urol 2014; 65 (2): 467-79.Berthold D.R et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival Analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.Attard G, Reid A.H, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8.Attard G, Reid A.H, De Bono J.S. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28 (29): e560-e561.Attard G, Reid A.H, Yap T.A et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration - resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71.Danila D.C, Morris M.J, De Bono J.S et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel - treated castration - resistant prostate cancer. J Clin Oncol 2010; 28:1496-501.Reid A.H, Attard G, Danila D.C et al. Significant and sustained antitumor activity in post docetaxel, castration - resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-95.Ryan C.J, Smith M.R, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-8.De Bono J.S, Logothetis C.J, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.Fizazi K, Scher H.I, Molina A. Abiraterone acetate for treatment of metastatic castration - resistant prostate cancer: final overall survival analysis of the COU- AA-301 randomised, double - blind, placebo - controlled phase 3 study. Lancet Oncol 2012; 13 (Issue 10): 983-99.Ryan C.J, Smith M.R, De Bono J.S. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368 (2): 138-48.Jr Goodman O.B et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration - resistant cancer. Prostate Cаncer Prostatic Dis 2014; 17: 34-9.Rathkopf D.E. Genitourinary Cancers Symposium. J Clin Oncol 2013; 31 (Suppl. 6): 5.